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Protamine sulfate is considered a weak anticoagulant, yet little is known concerning the mechanism 
of this effect or its relation to prior heparin exposure. This investigation defined the influence of 
increasing doses of protamine, with and without prior heparin anticoagulation, on the activated 
clotting time (ACT), thrombin clotting time (TCT), prothrombin time (PT), partial thromboplastin 
time (PTT), fibrinogen level, platelet count, and platelet aggregation to ADP in dogs (n = 8). Four 
doses of intravenous protamine sulfate (1.5, 3.0, 6.0, and 15.0 mg/kg) were studied in each animal, 
with at least 5 days between individual studies. Four dogs received heparin, 150 W/kg 10 min prior to 
protamine sulfate administration, and four dogs received protamine sulfate alone. Protamine sulfate 
caused anticoagulation, both in the presence and absence of heparin, with significant changes occur- 
ring in the ACT, PTT, platelet count, and platelet aggregation. Relevant changes did not occur in the 
TCT, PT, or fibrinogen levels. Platelet effects were capable of causing bleeding with standard or excess 
use of protamine sulfate, especially if platelet numbers were already decreased, as might occur in 
surgical procedures where thrombocytopenia commonly accompanies major blood loss and replace- 
ment. The ACT, reflecting both the coagulation cascade and platelet function, was the test most 
profoundly affected by protamine overdosage, and therefore may be misleading as a measure of 
protamine reversal of heparin. The TCT, which is sensitive to heparin anticoagulation but not prot- 
amine-induced anticoagulation, should be more accurate in differentiating inadequate heparin reversal 
from the effects of excess protamine. 0 1988 Academic Press, Inc. 
INTRODUCTION 
Postoperative bleeding continues to be a 
serious complication of cardiovascular sur- 
gery. Protamine sulfate is commonly used to 
reverse heparin anticoagulation. This sub- 
stance has been shown to have anticoagulant 
properties when used in large doses [ 1,2] and 
is known to cause platelet aggregation and 
profound decreases in platelet counts [3, 41. 
Compounding these events is the fact that 
protamine reversal of heparin may also cause 
adverse hemodynamic effects [4]. 
The activated clotting time (ACT) is often 
used intraoperatively to assess the effect of 
initial heparin dose and to titrate it’s later 
reversal [5, 61. This becomes important be- 
’ Sponsored in part by a grant from The American 
Heart Association of Michigan. 
2 Agents used in this study included beef lung heparin, 
Upjohn Co. (Kalamazoo, MI), and protamine sulfate, 
Eli Lilly and Co. (Indianapolis, IN). 
cause of the variable response to heparin re- 
sulting in potentially inadequate anticoagu- 
lation if a fixed heparin dose is based only on 
body weight, and if inadequate or excessive 
protamine administration at the time of hep- 
arin reversal is to be avoided. The ACT re- 
sponds in a linear fashion to increasing hepa- 
rin dosage and correlates well with the more 
cumbersome Lee-White clotting times [ 71. 
Many authors have alluded to the phenome- 
non of heparin rebound, with a slow return 
of heparin activity after apparent complete 
protamine reversal, as a limitation to titrat- 
ing protamine dosage with intraoperative 
clotting times [8,9]. This rebound phenome- 
non may be due to metabolism of protamine 
by serum proteases with release of heparin 
from heparin-protamine complexes [ lo]. 
Whatever the cause, it has been suggested 
that excess protamine be administered for 
heparin reversal in order to prevent a later 
anticoagulated state and possible bleeding [ 8, 
0022-4804/88 $1.50 
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91. Furthermore, it has been suggested that a 
moderate excess of protamine will not cause 
a clinically significant state of anticoagula- 
tion [ 111. 
The purpose of this investigation was to 
better define the anticoagulant action of 
protamine sulfate, both in the presence and 
absence of prior heparin administration, 
with specific attention to activated clotting 
times and platelets, as well as other standard 
parameters of coagulation. 
METHODS 
Eight awake adult female mongrel dogs 
weighing 20 to 30 kg received four different 
doses of protamine sulfate (1.5, 3.0, 6.0, and 
15.0 mg/kg) given intravenously over a 
5-min time period with at least a 5-day inter- 
val between studies of different doses in each 
subject. Four animals (Group I) were antico- 
agulated with intravenous sodium heparin, 
150 IU/kg, given as a bolus 10 min prior to 
protamine administration. Four other ani- 
mals (Group II) did not receive heparin prior 
to protamine administration. Blood speci- 
mens were obtained from a superficial limb 
vein prior to drug administration in all ani- 
mals, 5 min after heparin administration in 
animals that received heparin, and 5 minutes 
after completion of protamine administra- 
tion in all animals (Fig. 1). 
Blood for coagulation testing and platelet 
aggregation studies was drawn into evacu- 
ated tubes containing buffered citrate (Bec- 
ton-Dickinson, Rutherford, NJ). Tubes 
containing EDTA were used to collect blood 
for platelet counts. Platelin Plus Activator, 
composed of rabbit brain phospholipids and 
Celite, (Organon Teknika Co., Morris Plains, 
NJ), was used for the ACT assays. Data-Fi 
thrombin reagent was used for the thrombin 
clotting time (TCT) and fibrinogen determi- 
nations, with actin-activated cephaloplastin 
reagent used for measuring activated partial 
thromboplastin time (PTT), and thrombo- 
plastin-C rabbit brain thromboplastin with 
calcium reagent used for determining 
prothrombin times (PT), (all reagents from 
American Hospital Supply de1 Caribe, Inc., 
Aquada, Puerto Rico). The sodium salt of 
ADP, grade I/95-99%, (Sigma, St. Louis, 
MO) was used as the platelet aggregant. A 
TRIMED ACTester Model PA1000 (Hun- 
tington Beach, CA) was used for determina- 
tions of whole blood activated clotting times. 
The PT, PTT, TCT, and fibrinogen assays 
were performed with a fibrometer (Model 
604 15, Becton-Dickinson, Cockeysville, 
MD) and platelet aggregation studies were 
done using a dual-sample aggregation meter 
(Model DP-247-E, Sienco, Morrison, Co). 
The ACT was determined immediately 
after blood drawing by adding 0.2 ml of 
whole blood to 0.1 ml of Platelin Plus and 
then measuring the time of clot formation 
with the ACTester. For the other studies ci- 
trated blood was centrifuged at 800- 1000 
rpm for 5 min and the plasma was decanted 
as platelet rich plasma (PRP). These samples 
were then centrifuged at 1800-2000 rpm for 
an additional 10 min and the plasma was 
decanted as platelet poor plasma (PPP). The 
PPP was utilized for determination of the 
TCT, PT, PTT, and fibrinogen levels with 
the fibrometer. Platelet counts by phase-con- 
trast microscopy were done on the PRP sam- 
ples, so that platelet numbers could be stan- 
dardized for aggregation testing. Autologous 
PPP was used to dilute PRP to a platelet 
count of 200,000 or to the lowest platelet 
count in each animal’s baseline, postheparin, 
or postprotamine PRP samples, if any of 
these samples had counts less than 200,000. 
Platelet aggregation to ADP, at a concentra- 
tion of 1 pg/ml, was determined with the ag- 
gregometer calibrated such that 5% corre- 
sponded to untreated PRP and 95% corre- 
sponded to PPP. The maximum aggregation 
level in response to ADP was used as the 
index of platelet function in this study. 
Whole blood platelet counts were deter- 
mined on the EDTA blood samples by dilu- 
tion, red cell lysis, and phase-contrast mi- 
croscopy. 
Data were assessed using actual test values 
and also as the ratio or percentage of post- 
treatment values compared to baseline 
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values for each animal. A nonparametric 
median test was used to compare post-treat- 
ment values to the baseline values. Data in 
this work are expressed as the X +- 1 SD. 
Animal care complied with the Principles of 
Laboratory Animal Care and the Guide for 
the Care and Use of Laboratory Animals 
(NIH Publication No. 80-23, Revised 1976). 
RESULTS 
ACT baseline values in Group I ranged 
from 69 to 108 set with a mean of 94 st 10 
set (n = 15). After administering 150 III/kg 
of heparin, the ACT ranged from 225 to 
more than 1000 set ( 1000 being the maxi- 
mum value measured on the ACTester). This 
corresponded to an increase of 2.3 to greater 
than 14.5 times the baseline value (3.7 
+ 4.5). TCT increased 7.5- to 20-fold after 
heparin administration. Increases in PTT 
were 1.6- to 5.2-fold, and increases in PT 
were 0.9 to 1.7 times baseline values. Hepa- 
rin administration did not cause statistically 
significant changes in fibrinogen (range 80 to 
117% of baseline) or platelet counts (68 to 
119% of baseline). The platelet aggregation 
response to heparin varied widely (61 to 
600% of baseline). Some animals exhibited 
increased aggregation and some had de- 
creased platelet aggregation after heparin, re- 
sulting in no overall significant differences. 
In Group II the ACT baseline values ranged 
from 77 to 135 set (101 + 15). 
Coagulation tests in this investigation were 
expressed in absolute terms or in comparison 
to baseline values (Tables 1 and 2). Normal- 
ized values for the ACT, TCT, PT, and PTT 
tests in this study were defined as a ratio to 
baseline, whereas normalized values for fi- 
brinogen level, platelet count, and platelet 
aggregation were expressed as a percentage of 
the baseline (Figs. 2 and 3). 
A protamine reversal dose of 1.5 mg/kg, 
corresponding to 1 mg protamine for each 
100 units of heparin, returned coagulation 
tests altered by heparin to baseline values. 
The 1.5 mg/kg dose of protamine did not 
produce significant anticoagulation. Prot- 
amine administration in increasing doses re- 
sulted in progressive prolongation of the 
ACT and PTT. Progressively larger decreases 
in platelet counts also occurred with increas- 
ing protamine dose. Diminutions in platelet 
counts became dramatic with protamine 
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I- I- 
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FIG. 1. Study design. 
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TABLE 1 
EFFECTS OF INCREASING L~XES OF PROTAMINE ON COAGULATION 
IN GROUP I ANIMALS WITH PRIOR HEPARIN (150 IU/kg) 
Protamine dose (mg/kg) 1.5 3.0 6.0 15.0 
Actual 
ACT (set) 99.0 + 21.0 109.0 f  5.0* 171.0 2 47.0: 86 1 .O of: 278.0* 
TCT (set) 7.1 + 2.2 6.1 + 0.7 6.3 f  1.2 6.4 f  1.0 
PT (set) 7.1 f  0.6 6.9 + 0.6 7.1 f  0.5 1.7 f  1.2 
PTT (set) 12.6? 1.4 11.4 f  1.5 13.3 f  1.0 33.4 f  28.8* 
Fibrinogen (mg/dl) 244.0 ?I 83.0 310.0 + 173.0 367.0 rf: 214.0 267.0 + 217.0 
Platelet count (number/mm’) 159.0 f  81.0 162.0 f  107.0 159.0 f  115.0 44.0 f  41.0* 
Platelet aggregation (max %) 27.0 f  6.0 24.0 f  10.0 13.0 f  2.0; N/A” 
Normalized 
ACT 1.1 * 0.3 1.2 f  0.1; 1.7 f  0.5* 10.1 f  4.3* 
TCT 1.1 + 0.4 1.0* 0.1 1.0 * 0.1 1.1 f  0.1 
PT 1.1 f  0.1 l.O? 0.1 1.1 f  0.1 1.1 + 0.2 
PTT 1.2 f  0.1 1.1 f  0.1 1.3 * 0.1 3.2 zk 2.8* 
Fibrinogen 94.0 + 15.0% 89.0 + 22.0% 100.0 + 8.0% 70.0 + 19.0% 
Platelet count 45.0 f  15.0% 41.0 f  7.0% 35.0 Ifr 17.0% 10.0 + 9.0%* 
Platelet aggregation 99.0 2 67.0% 59.0 + 19.0% 45.0 f  17.0%* N/A” 
Note. Data are expressed as means f  standard deviations for actual values and data normalized to baseline 
(preheparin) values. 
’ Low platelet count precluded aggregation testing. 
* P < 0.05. 
overdosage, and platelet clumping was ob- 
served by phase microscopy after protamine 
administration. Similarly, a progressive drop 
in platelet aggregation occurred in response 
to ADP with increasing doses of protamine. 
Aggregation studies could not be done with 
the 15.0 mg/kg protamine dose because the 
platelet count was too low. TCT, PT, and 
fibrinogen levels did not reflect the anticoag- 
ulant properties of protamine. The afore- 
noted changes in the coagulation system oc- 
curring with protamine overdosage were 
similar in both heparinized and nonheparin- 
ized animals. 
DISCUSSION 
Significant anticoagulant properties of 
protamine sulfate were documented in this 
study, with demonstrated effects noted on 
both platelet function and the coagulation 
cascade. The drop in platelet count asso- 
ciated with protamine sulfate reversal of hep- 
arin has been well documented previously [2, 
41. This phenomenon is most likely second- 
ary to the platelet aggregatory properties of 
protamine sulfate [3]. Platelets are known to 
be sequestered in the lung after protamine 
administration [ 121. Protamine-induced 
platelet aggregation as a cause of the throm- 
bocytopenia was consistent with the platelet 
aggregates seen on phase microscopy in our 
samples. Protamine-induced platelet aggre- 
gation may be due to its direct effect on 
platelet membranes or it could be mediated 
by recognized aggregants such as thrombin. 
In this regard, protamine is known to inter- 
fere with thrombin neutralization by an- 
tithrombin III and also thrombin binding to 
thrombomodulin [ 13, 141. Blocking these 
neutralizers of thrombin’s procoagulant ac- 
tion may make more thrombin available for 
binding to platelet receptors, thus resulting 
in platelet aggregation. 
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In this study, diminutions in platelet 
counts were progressively greater with in- 
creasing protamine doses. The impressive 
thrombocytopenia occurring with protamine 
overdosage under these circumstances could 
result in bleeding. A drop in platelet count to 
20 to 30% of baseline with a protamine re- 
versal dose of 1.5 mg/ 100 units of heparin 
has been seen in earlier studies from our lab- 
oratory [ 15, 161, and we have noted a drop to 
73% of baseline in humans using this same 
reversal dose [ 171. It is possible that human 
platelets are less sensitive to protamine or 
that medications inhibiting platelet aggrega- 
tion in patients are responsible for the lesser 
degree of protamine-induced thrombocyto- 
penia occurring in humans. 
Platelet aggregation to ADP was progres- 
sively inhibited by increasing doses of prot- 
amine in this study. In a previous experi- 
ment from our laboratory using platelets ex- 
posed to exogenous protamine, inhibition of 
thrombin-induced platelet aggregation oc- 
curred, but ADP-induced platelet aggrega- 
tion was not inhibited [ 181. Since protamine 
is a platelet aggregant, it is possible that the 
apparent drop in platelet aggregation is a re- 
sult of selecting out the more responsive 
platelets by protamine, rather than actual 
protamine inhibition of platelet aggregation. 
In any case, the end result of protamine ad- 
ministration is a lowered number of platelets 
and a lessened response to platelet aggre- 
gants. 
The coagulation cascade also appears to be 
affected by protamine sulfate administra- 
tion. Protamine’s greater effect on the PTT 
than the PT suggests that enzymes or cofac- 
tors of the intrinsic pathway are more sensi- 
tive to this substance. Failure of protamine 
to affect the TCT suggests that inhibition of 
thrombin-catalyzed conversion of fibrinogen 
does not contribute significantly to prot- 
amine’s anticoagulant effect. Protamine is a 
TABLE 2 
EFFECTS OF INCREASING DOSES OF PROTAMINE ON COAGULATION 
IN GROUP II ANIMALS WITHOUT PRIOR HEPARIN 
Protamine dose (me/kg) 1.5 3.0 6.0 15.0 
Actual 
ACT (set) 102.0 + 10.0 134.0 f 18.0* 313.0 + 215.0* 1000.0 + o.o* 
TCT (set) 6.8 + 1.5 6.6 + 0.5 6.5 f 1.5 6.2 f 1.0 
PT (=I 6.9 + 0.5 7.1 + 0.6 7.4 f 1.0 8.2 f 0.4; 
PTT (set) 11.4* 1.2 11.1 + 1.6 15.7 f 5.0* 29.9 + 5.4+ 
Fibrinogen (mg/dl) 460.0 +- 240.0 422.0 f 244.0 340.0 f 139.0 316.0 + 170.0 
Platelet count (number/mm’) 328.0 + 161.0 140.0 + 54.0* 56.0 f 32.0* 55.0 ?I 48.0* 
Platelet aggregation (max %) 38.0+ 21.0 35.0 + 17.0* 28.0 f 8.0* N/A” 
Normalized 
ACT 1.0* 0.1 1.4 f 0.3* 3.2 f 2.1* 9.7 f 2.4* 
TCT 1.0 * 0.1 1.02 0.1 l.Of 0.1 0.9 f 0.1 
PT 1.0 + 0.1 1.0 f 0.1 1.1 * 0.1 1.3 f 0.1; 
PTT 1.0 + 0.1 1.1 f 0.1 1.5 f 0.5; 2.7 + 0.3* 
Fibrinogen 107.0 + 18.0% 98.0 f 6.0% 96.0 f 4.0% 85.0 + 14.0% 
Platelet count 88.0 A 5.0% 46.0 + 25.0%* 14.0 f 7.0%f 13.0 + lo.o%* 
Platelet aggregation 63.0 f 26.0% 5 1.0 + 28.0%* 37.0 -t 1 .o%* N/A’ 
Note. Data are expressed as means f standard deviations for actual values and data normalized to baseline 
(pre-protamine) values. 
(1 Low platelet count precluded aggregation testing. 
*P < 0.05. 
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1.5 3.0 8.0 15.0 1.5 3.0 80 15.0 
PROTAMINE DOSE PROTAMNE DOSE 
PROTAMINE DOSE PROTAMNE DOSE 
FIG. 2. Effects of increasing protamine dose on acti- 
vated clotting time (ACT), thrombin clotting time 
(TCT), prothrombin time (PT), and partial thrombo- 
plastin time (PTT). Error bars represent standard devia- 
tions. *P < 0.05. 
substrate for thrombin, and has been shown 
to block thrombin conversion of fibrinogen 
in an in vitro assay [ 191. In the present study 
this property did not appear to be an impor- 
tant factor in the protamine-associated state 
of anticoagulation. The results of this inves- 
tigation imply that inhibition of the protease 
factors XII, XI, and IX or the protease co- 
factor factor VIII contributes to the anticoag- 
ulant effects of protamine. Inhibition of fac- 
tor XI by protamine has been demon- 
strated [20]. 
ACT appears to be the clotting assay most 
sensitive to the anticoagulant properties of 
protamine sulfate. Since ACT is a whole 
blood clotting study, it’s sensitivity could be 
explained by protamine’s dual effect on both 
platelets and the coagulation cascade. Al- 
though the ACT may best reveal the overall 
state of anticoagulation, it may be mislead- 
ing when used as a guide for protamine sul- 
fate reversal of heparin. Considerable error 
may exist if a prolonged ACT following prot- 
amine sulfate reversal of heparin is inter- 
preted as always indicating incomplete re- 
versal. Indeed, prolonged ACT values can 
reflect other causes of anticoagulation in- 
cluding excess protamine. Administration of 
additional protamine under such circum- 
stances may only heighten the degree of ex- 
isting anticoagulation. Since the TCT is a 
sensitive and accurate indicator of heparin 
activity and is not significantly affected by 
protamine excess, it should be more accurate 
in differentiating inadequate heparin reversal 
from protamine overdose. The TCT is af- 
fected only by fibrinogen concentration and 
thrombin inhibitors. Perhaps a modified ac- 
tivated whole blood clotting time with 
thrombin as the activating agent would be 
more useful for intraoperative monitoring of 
heparin activity and it’s reversal with prot- 
amine. 
Protamine sulfate acts as an anticoagulant 
with effects on platelets and the intrinsic co- 
agulation pathway. These effects should not 
lead to significant anticoagulation with stan- 
dard doses of protamine if the coagulation 
system is normal. However, the antiplatelet 
Platelet 
PIWTAMNE DOSE PROTAMINE DOSE 
Fibrinogen 
PFOTAMINE DOSE 
FIG. 3. Effects of increasing protamine dose on platelet 
count, platelet aggregation to ADP, and fibrinogen. 
Error bars represent standard deviations. *P < 0.05. 
14 JOURNAL OF SURGICAL RESEARCH: VOL. 45, NO. 1, JULY 1988 
properties of protamine sulfate may become 10. 
more important in the face of prexisting 
thrombocytopenia or altered platelet func- 
tion. The ACT reflects the combined antico- 
11. 
agulant and antiplatelet effects of protamine. 
Thus, a prolonged ACT after protamine re- 12. 
versa1 of heparin may be misleading if it is 
routinely interpreted as indicating inade- 
quate reversal. The TCT is not affected by 
large excesses of protamine and is therefore 
considered a more reliable indicator of resid- 
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